Lene Kongsgaard Nielsen

University of Southern Denmark — Denmark

Medicine · Health Sciences

15h-index792citations119works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(44), Cancer Treatment and Pharmacology(26), Health Systems, Economic Evaluations, Quality of Life(10), Myeloproliferative Neoplasms: Diagnosis and Treatment(8), Protein Degradation and Inhibitors(7)

Publications117 total

A Once-Weekly C-Type Natriuretic Peptide for Treatment of Heart Failure with Preserved Ejection Fraction
Journal of Medicinal Chemistry·2025
Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.
Blood·2025Open Access
Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; Results from the nmsg rest study
Blood·2025Open Access
A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
Clinical Lymphoma Myeloma & Leukemia·2025
Effectiveness, Safety and Clinical use of Teclistamab in Patients with Triple-Class-Exposed Multiple Myeloma. Data from the Danish ABC-Study
Clinical Lymphoma Myeloma & Leukemia·2025
Update of the EORTC Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20). Results from the Phase I-II EORTC Prospective Study
Clinical Lymphoma Myeloma & Leukemia·2025
Numerical Prediction of Wave-Runup on a Monopile With the Direct Surface Description Method
2025Open Access
Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO)
Journal of Patient-Reported Outcomes·2025· 1 citedOpen Access
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
The Lancet Haematology·2025· 10 cited
Limited Benefit of Routine Clinical Follow‐Up for Relapse Detection in Diffuse Large B‐Cell Lymphoma Patients in Complete Remission Following First‐Line Treatment
American Journal of Hematology·2025Open Access
Cross-Cultural Adaptation and Psychometric Validation of the Danish and Norwegian Versions of the Steroid Symptom Questionnaire for Multiple Myeloma (SSQ-MM)
University of Southern Denmark Research Portal (University of Southern Denmark)·2025
Results from qualitative interviews with patients and healthcare professionals
2025
Real-world effectiveness of belantamab mafodotin, BCMA-CD3 bispecific antibodies and talquetamab in patients with triple-class-exposed multiple myeloma. First results from the Danish ABCD-study
2025
Health‐Related Quality of Life During Carfilzomib–Lenalidomide–Dexamethasone Consolidation: Findings From the Multiple Myeloma <scp>CONPET</scp> Study
European Journal Of Haematology·2024Open Access
A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group
Blood·2024· 1 cited
Krd Consolidation Abrogates Poor Prognosis of FDG PET/CT Positivity after ASCT: Results from a Phase II Study (CONPET)
Blood·2024Open Access
Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms
Quality of Life Research·2024· 4 citedOpen Access
Arfilzomib-lenalidomide-dexamethasone consolidation after upfront autologous stemcell transplantation caused no significant patient-reported shortness of breath: findings fromthe conpet study
University of Southern Denmark Research Portal (University of Southern Denmark)·2024
Transition of care in a Danish context: translation, cross-cultural adaptation and content validation of CTM-15 and PACT-M
Journal of Patient-Reported Outcomes·2024· 4 citedOpen Access
Carfilzomib-lenalidomide-dexamethasone consolidation after upfront autologous stem cell transplantation caused no significant patient-reported shortness of breath: findings from the CONPET study
2024
page 1 of 6Next →

Frequent Co-authors

Niels Abildgaard(17), Henrik Frederiksen(10), Mary Jarden(8), Christen Lykkegaard Andersen(8), Henrik Gregersen(8), Sören Möller(7), Fredrik Schjesvold(7), Mikael Frederiksen(5), Annette Juul Vangsted(5), Madeleine King(4), Anja Klostergaard(4), Morten Steffensen(4), Per Trøllund Pedersen(4), Maja Hinge(4), Carsten Helleberg(4), Morten Salomo(4), Einar Haukås(4), Peter Gimsing(4), Louise Redder(4), Tobias Wirenfeldt Klausen(4)